# Calidi Biotherapeutics, Inc. (CLDI) · Edgar & Edgarette company card

> Calidi Biotherapeutics (CLDI) reported revenue of $0 million in FY2022, operating margin -51396% against a -15.8% median for biological products, (no diagnostic substances), equity -1942% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1855485 · fiscal year ended 2022-12-31 · 1 audited years read · [page](https://www.pops4.com/boards/company/CLDI) · [JSON](https://www.pops4.com/boards/company/CLDI.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $45,000 |
| Revenue growth, 1 year | — |
| Revenue growth per year | — |
| Operating margin | -51395.6% |
| Net margin | -56504.4% |
| Operating cash flow | −$13M |
| Capital spending | — |
| Free cash flow | — |
| Cash | $590,000 |
| Long-term debt | — |
| Total assets | $3M |
| Total equity | −$50M |
| Equity ÷ assets | -1942.2% |
| Return on equity | — |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: -255.99 (distress zone)
- Health Harbor boat: Sound ship · one warning sign · operating cash flow was negative (-$21.3M in FY2025)

## Edgarette's reading

Exposure: revenue $45K (FY2022). Experience: one year on record; operating margin -51395.6%. Soundness: equity -1942.2% of assets (liabilities exceed assets). Credibility: one audited year, little weight. Against peers (31 filers, $50M+ revenue, biological products, (no diagnostic substances)): operating margin -51395.6% against a -15.8% median.

## Health Watch, last 12 months

- Item 3.01 Exchange listing notice or transfer: 1, latest 2026-09-25 ([filing](https://www.sec.gov/Archives/edgar/data/1855485/000149315226044381/0001493152-26-044381-index.htm))
- Item 5.02 Director or officer change: 2, latest 2026-06-23 ([filing](https://www.sec.gov/Archives/edgar/data/1855485/000149315226029710/0001493152-26-029710-index.htm))

## Recent filings

- 8-K · filed 2026-09-25 · 3.01 Notice of Delisting or Failure to Satisfy a Listing Rule; 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1855485/000149315226044381/0001493152-26-044381-index.htm)
- 8-K · filed 2026-09-22 · 1.01 Entry into a Material Definitive Agreement; 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1855485/000149315226043724/0001493152-26-043724-index.htm)
- 10-Q · filed 2026-08-13 · [filing](https://www.sec.gov/Archives/edgar/data/1855485/000149315226037847/0001493152-26-037847-index.htm)
- 8-K · filed 2026-08-13 · 2.02 Results of Operations and Financial Condition; 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1855485/000149315226037840/0001493152-26-037840-index.htm)
- 8-K · filed 2026-07-31 · 3.03 Material Modifications to Rights of Security Holders; 5.03 Amendments to Articles or Bylaws; Change in Fiscal Year; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1855485/000149315226035666/0001493152-26-035666-index.htm)
- 8-K · filed 2026-07-16 · 1.01 Entry into a Material Definitive Agreement; 1.02 Termination of a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1855485/000149315226033594/0001493152-26-033594-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001855485.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1855485

## Cite

POPS4, Edgar & Edgarette: Calidi Biotherapeutics, Inc. (CLDI) company card, from the company's own SEC filings, accessed 2026-11-07, https://www.pops4.com/boards/company/CLDI. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Its latest audited year is FY2025, which reports no revenue; the revenue figures and the range here are from FY2022, its last year with revenue on record. Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.